EFM
BPMC

E Fund Management’s Blueprint Medicines BPMC Stock Holding History

E Fund Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$867K Sell
6,761
-2,521
-27% -$262K 0.04% 183
2025
Q1 		$822K Buy
9,282
+2,964
+47% +$289K 0.04% 185
2024
Q4 		$551K Sell
6,318
-1,190
-16% -$109K 0.03% 215
2024
Q3 		$694K Buy
7,508
+1,740
+30% +$173K 0.04% 168
2024
Q2 		$622K Buy
5,768
+1,073
+23% +$107K 0.03% 157
2024
Q1 		$445K Sell
4,695
-1,798
-28% -$154K 0.03% 177
2023
Q4 		$599K Sell
6,493
-2,072
-24% -$134K 0.04% 126
2023
Q3 		$430K Buy
8,565
+926
+12% +$49.5K 0.03% 151
2023
Q2 		$483K Sell
7,639
-1,556
-17% -$84.6K 0.04% 116
2023
Q1 		$414K Buy
9,195
+267
+3% +$12K 0.03% 154
2022
Q4 		$391K Buy
8,928
+2,666
+43% +$128K 0.03% 187
2022
Q3 		$413K Sell
6,262
-2,847
-31% -$183K 0.04% 174
2022
Q2 		$460K Buy
9,109
+4,411
+94% +$258K 0.04% 159
2022
Q1 		$300K Buy
+4,698
New +$337K 0.01% 193

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

E Fund Management's BPMC Position: Q2 2025 in Review

E Fund Management reduced its Blueprint Medicines (BPMC) stake by 27% in Q2 2025, selling an estimated $262K and leaving 6,761 shares worth $867K. The position accounts for 0.04% of the portfolio, ranked #183.

E Fund Management first reported a position in BPMC in Q1 2022 and has held it in 14 quarters since. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • E Fund Management held 6,761 shares of Blueprint Medicines worth $867K as of Q2 2025.
  • E Fund Management sold 2,521 Blueprint Medicines shares in Q2 2025, an estimated $262K.
  • Blueprint Medicines made up 0.04% of E Fund Management's portfolio in Q2 2025, its #183 holding.
  • E Fund Management first reported a position in Blueprint Medicines in Q1 2022 and has held it in 14 quarters since.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on E Fund Management's 13F filing for Q2 2025, filed 15 Aug 2025.